Palvella Therapeutics, Inc. (PVLA) — 10-Q Filings

10-Q Filings (6)

• Palvella's Losses Double Amid Soaring R&D, Cash Dwindles — Nov 12, 2025 Risk: high
  Palvella Therapeutics, Inc. (PVLA) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $29.001 million, up from $
• Palvella's Losses Mount Post-Merger Amid Soaring R&D Costs — Aug 14, 2025 Risk: high
  Palvella Therapeutics, Inc. (PVLA) reported a significant increase in net loss and operating expenses for the six months ended June 30, 2025, following its Reve
• Palvella Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Palvella Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Pieris Pharmaceuticals, Inc., is incorporated in
• Pieris Pharmaceuticals Q3 2024: Net Loss of $12.5M — Nov 13, 2024 Risk: medium
  Pieris Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $14.2 million and total liabilities o
• Pieris Pharma Q2 2024: $0.7M Revenue, $12.5M Cash — Aug 14, 2024 Risk: medium
  Pieris Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported $0.7 million in revenue for the three months ended June 30
• Pieris Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  PIERIS PHARMACEUTICALS, INC. (PVLA) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Pieris Pharmaceuticals reported $1,236,688 in revenue for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX